Compare PTLO & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTLO | PLYX |
|---|---|---|
| Founded | 1963 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 323.5M | 271.8M |
| IPO Year | 2021 | N/A |
| Metric | PTLO | PLYX |
|---|---|---|
| Price | $4.18 | $2.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 1 |
| Target Price | $8.06 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 1.5M | 297.0K |
| Earning Date | 05-05-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $732,066,000.00 | N/A |
| Revenue This Year | $9.02 | N/A |
| Revenue Next Year | $5.81 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.03 | N/A |
| 52 Week Low | $3.78 | $2.01 |
| 52 Week High | $11.82 | $9.18 |
| Indicator | PTLO | PLYX |
|---|---|---|
| Relative Strength Index (RSI) | 47.51 | 37.92 |
| Support Level | $3.79 | $2.04 |
| Resistance Level | $4.40 | $3.41 |
| Average True Range (ATR) | 0.22 | 0.27 |
| MACD | 0.08 | 0.06 |
| Stochastic Oscillator | 60.25 | 23.31 |
Portillos Inc serves the Chicago street food industry through high-energy and multichannel restaurants designed to ignite the senses and create memorable dining experiences. The company owns and operates fast-casual restaurants in the United States, along with two food production commissaries in Illinois. Its menu includes hot dogs, beef and sausage sandwiches, sandwiches and ribs, salads, burgers, chicken, sides and soup, and others.
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.